The Perioperative Period of Heart Transplantation Is Affected by Thyroid Hormone Status.
Balázs SzécsiRichárd SinkóAlexandra VerebDmitry KhochanskiyKálmán BenkeTamás RadovitsBálint LakatosAndrea KőszegiEszter LosonczSzilvia KuglerMárk SzabóBéla MerkelyAndrea SzékelyBalázs GerebenPublished in: Thyroid : official journal of the American Thyroid Association (2024)
Background: Orthotopic heart transplantation (HTx) is a long-term surgical therapeutic approach for patients with end-stage heart failure. The objective of the present study was to uncover associations between altered thyroid hormone (TH) status and adverse outcomes after HTx. Methods: In this prospective, single-center cohort study, 283 patients underwent HTx between 2013 and 2020 at the Heart and Vascular Center of Semmelweis University in Hungary. We measured serum free triiodothyronine (fT3), free thyroxine (fT4), and thyrotropin (TSH) pre- and postoperatively. TaqMan qPCR was used to measure type 2 deiodinase and type 3 deiodinase mRNA ( Dio2 and Dio3 , respectively) levels from the diseased heart bioptates. To assess the local TH action of the heart, mRNA levels of Hcn2 and Myh7 were measured in a subgroup of patients receiving extracorporeal membrane oxygenation (ECMO) postoperatively. Groups were compared using nonparametric tests. Cox regression analysis and logistic regression test were used to investigate the outcomes. The connection between serum TH parameters and cardiac gene expressions was assessed using linear regression. Results: Serum TSH ( p = 0.009), fT3 ( p < 0.001), and fT4 ( p < 0.001) levels were lower after HTx than preoperatively. Levothyroxine (LT4) administered to donors was associated with better survival after 30 days ( p = 0.049). LT4 replacement given to recipients after HTx was associated with better survival after 30 days ( p = 0.018), 1 year ( p = 0.002), and 2 years ( p = 0.001). Dio3 mRNA level was significantly increased in patients who were treated with ECMO ( p = 0.026), left ventricular assist device (LVAD) ( p = 0.008), and biventricular assist device (BiVAD) ( p = 0.013) preoperatively, and ECMO ( p = 0.042) postoperatively, compared with those who did not require any type of mechanical circulatory support (MCS). We found no significant difference in the expression of the Hcn2 and Myh7 marker genes between patients on postoperative ECMO and those without MCS, and neither did they correlate with serum hormone levels ( p = 0.519 and p = 0.056, respectively). Conclusions: We conclude that TH status plays an important role in HTx patients, and monitoring of TH status in the perioperative period may contribute to improved treatment outcomes. Our findings require independent confirmation in a randomized controlled clinical trial.
Keyphrases
- extracorporeal membrane oxygenation
- heart failure
- end stage renal disease
- acute respiratory distress syndrome
- newly diagnosed
- chronic kidney disease
- ejection fraction
- patients undergoing
- peritoneal dialysis
- left ventricular assist device
- prognostic factors
- poor prognosis
- randomized controlled trial
- patient reported outcomes
- metabolic syndrome
- left ventricular
- gene expression
- binding protein
- clinical trial
- transcription factor
- insulin resistance
- emergency department
- kidney transplantation
- skeletal muscle
- hypertrophic cardiomyopathy
- weight loss
- long non coding rna
- patient reported
- genome wide analysis